COVID-19 vaccination with bacterial peptide conjugated to receptor-binding area elicits potent immune response

In a latest examine revealed within the iScience journal, researchers assessed the effectivity of immunization with a bacterial peptide conjugated to the extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding area towards SARS-CoV-2 an infection.

Study: Vaccination with a bacterial peptide conjugated to SARS-CoV-2 RBD accelerates immunity and protects against COVID-19. Image Credit: BaLL LunLa/Shutterstock
Research: Vaccination with a bacterial peptide conjugated to SARS-CoV-2 RBD accelerates immunity and protects against COVID-19. Picture Credit score: BaLL LunLa/Shutterstock

The fixed emergence of novel SARS-CoV-2 variants has adversely affected the efficacy and affect of coronavirus illness 2019 (COVID-19) vaccines towards infections and illness severity. Therefore, new vaccine platforms are wanted to develop efficient and secure vaccination regimens towards SARS-CoV-2 infections and associated hospitalization.   

In regards to the examine

Within the current examine, researchers employed immune Enhance (iBoost) expertise to enhance the response of the immune system towards the SARS-CoV-2 spike (S) RBD.

The staff achieved immune recognition of SARS-CoV-2 RBD by conjugating the sequence to a chimeric designer peptide (CDP) engineered by the researchers. The CDP includes clusters of amino acids having both charged facet chains or cumbersome hydrophilic teams, derived from three totally different bacterial proteins, particularly ZapB which is the cell division protein, IbpA which is a small warmth shock protein, and TFP (kind I fimbrial protein). The developed conjugate protein named CPD-RBD was expressed and purified.

The immunogenicity of the conjugated CPD-RBD in vivo was assessed and in comparison with the corresponding unconjugated RBD by immunizing BALB/c mice with every purified protein on day 0 by main vaccination and on day 14 by a booster vaccination. The staff chosen Montanide ISA 720 together with a toll-like receptor 9 agonist referred to as CpG 1826 oligonucleotide as a vaccine adjuvant. Serological samples had been collected from the mice earlier than immunization on day 0 and on days 13, 21, 28, and 35. The samples had been additional analyzed for the presence of anti-RBD antibodies utilizing an enzyme-linked immunosorbent assay (ELISA).

Moreover, the staff assessed the manufacturing of IgG1 and IgG2b, which represented T-helper (Th)-2-skewed immune responses, and IgG2a and IgG3, which correlated with the stimulation of a Th1 response. The researchers additionally immunized mice with CPD-RBD or RBD alone together with the Sepivac (Sep), which was a vaccine adjuvant used as a substitute of Montanide.


The examine outcomes confirmed that including the DCP element to the SARS-CoV-2 RBD elevated the solubility in addition to the protein yield of the ensuing conjugate protein CPD-RBD. The in silico evaluation of the sequence of the conjugate protein displayed the alpha-helix or beta-strand domains. Moreover, the B-cell and T-cell epitopes noticed within the in silico evaluation indicated potent immune recognition. 

The staff discovered no antibodies towards SARS-CoV-2 RBD within the pre-immune serum samples collected on day 0. Nonetheless, seroconversion was noticed by day 13 in a number of mice belonging to each the teams that had been vaccinated by the conjugated and the unconjugated purified proteins. Furthermore, by day 21, all of the mice that obtained the CPD-RBD vaccine displayed strong immunoglobulin (Ig) ranges towards viral RBD. Additionally, by day 21, solely 50% of the mice immunized by the RBD revealed a powerful RBD-specific humoral response whereas no anti-RBD antibodies had been present in two out of the ten mice vaccinated with unconjugated RBD protein. This instructed that the RBD had average immunogenicity.

Moreover, the distinction within the complete anti-RBD Ig ranges between the 2 vaccinated cohorts diminished at subsequent time factors. Nonetheless, the antibody titers akin to the RBD-immunized mice had been decrease than the CPD-RBD vaccinees three weeks after the mice had been vaccinated with the booster dose. This indicated that the iBoost platform elicited sooner and extra strong anti-RBD antibody responses as in comparison with RBD alone.

Evaluation of the IgG subclasses confirmed that by day 21, the mice immunized with CDP-RBD had considerably greater concentrations of each anti-RBD IgG3 and IgG1 as in comparison with the RBD-vaccinated mice. Furthermore, the staff famous a development of more and more strong and constant IgG2 response among the many CDP-RBD-immunized mice. Additionally, vaccination with CDP-RBD, and never unconjugated with RBD, resulted in a better functionality of mounting full IgG1, IgG2a, IgG2b, and IgG3 responses. Thus, the CPD-RBD vaccine confirmed a extra complete response towards SARS-CoV-2 RBD, even seven days post-booster vaccination. 

Evaluation with Sep because the vaccine adjuvant revealed that CDP-RBD/Sep induced greater ranges of anti-RBD complete IgG as in comparison with the RBD/Sep vaccine, which was additionally noticed for CDP-RBD with Montanide. This indicated that CDP was the important thing element that boosted the humoral immune response. Furthermore, a surrogate neutralization assay confirmed that serum obtained from the CPD-RBD-immunized vaccine resulted in greater ranges of inhibition of RBD-angiotensin-converting enzyme-2 (ACE-2) binding from day 21 onwards as in comparison with serum obtained from mice that had been immunized with RBD alone.


Total, the examine findings confirmed that the CPD-RBD vaccination elicited a potent immune response and in addition protected towards the extreme signs related to COVID-19.

Journal reference:



Leave a Reply